Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
7 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
The Safety and Immunogenicity of the mRNA-BNT162b2 SARS-CoV-2 Vaccine in Hemodialysis Patients.
Front Immunol. 2021 Jun 16;12:704773. doi: 10.3389/fimmu.2021.704773. eCollection 2021.
Front Immunol. 2021.
PMID: 34220867
Free PMC article.
Serological SARS-CoV-2 antibody response, potential predictive markers and safety of BNT162b2 mRNA COVID-19 vaccine in haematological and oncological patients.
Benda M, Mutschlechner B, Ulmer H, Grabher C, Severgnini L, Volgger A, Reimann P, Lang T, Atzl M, Huynh M, Gasser K, Petrausch U, Fraunberger P, Hartmann B, Winder T.
Benda M, et al.
Br J Haematol. 2021 Nov;195(4):523-531. doi: 10.1111/bjh.17743. Epub 2021 Aug 3.
Br J Haematol. 2021.
PMID: 34346068
Free PMC article.
Item in Clipboard
Efficacy and safety of heterologous booster vaccination with Ad26.COV2.S after BNT162b2 mRNA COVID-19 vaccine in haemato-oncological patients with no antibody response.
Reimann P, Ulmer H, Mutschlechner B, Benda M, Severgnini L, Volgger A, Lang T, Atzl M, Huynh M, Gasser K, Grabher C, Mink S, Fraunberger P, Petrausch U, Hartmann B, Winder T.
Reimann P, et al.
Br J Haematol. 2022 Feb;196(3):577-584. doi: 10.1111/bjh.17982. Epub 2021 Dec 6.
Br J Haematol. 2022.
PMID: 34872162
Clinical Trial.
Item in Clipboard
SARS-CoV-2 RBD-specific and NP-specific antibody response of healthcare workers in the westernmost Austrian state Vorarlberg: a prospective cohort study.
Atzl M, Muendlein A, Winder T, Fraunberger P, Brandtner EM, Geiger K, Klausberger M, Duerkop M, Sprenger L, Mutschlechner B, Volgger A, Benda M, Severgnini L, Jaeger JB, Drexel H, Lang A, Leiherer A.
Atzl M, et al.
BMJ Open. 2022 May 24;12(5):e052130. doi: 10.1136/bmjopen-2021-052130.
BMJ Open. 2022.
PMID: 35613821
Free PMC article.
Item in Clipboard
Attrition Rates in Multiple Myeloma Treatment under Real World Conditions-An Analysis from the Austrian Myeloma Registry (AMR).
Benda MA, Ulmer H, Weger R, Reimann P, Lang T, Pichler P, Winder T, Hartmann B, Strassl I, Krauth MT, Agis H, Sormann S, Podar K, Willenbacher W, Willenbacher E.
Benda MA, et al.
Cancers (Basel). 2023 Feb 2;15(3):962. doi: 10.3390/cancers15030962.
Cancers (Basel). 2023.
PMID: 36765918
Free PMC article.
Item in Clipboard
Efficacy and safety of tixagevimab/cilgavimab as passive immunisation against COVID-19 infections in patients with hematological malignancies.
Reimann P, Petzer V, Mündlein A, Hartmann B, Severgnini L, Winkler A, Lang T, Huynh M, Gasser K, Rüger J, Atzl M, Mink S, Fraunberger P, Schmidt S, Steiner N, Griesmacher A, Gunsilius E, Nachbaur D, Willenbacher W, Wolf D, Winder T, Benda MA.
Reimann P, et al. Among authors: benda ma.
Ann Hematol. 2024 Jun;103(6):2123-2131. doi: 10.1007/s00277-024-05671-6. Epub 2024 Mar 2.
Ann Hematol. 2024.
PMID: 38436671
Item in Clipboard
Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study.
Piccini JP, Caso V, Connolly SJ, Fox KAA, Oldgren J, Jones WS, Gorog DA, Durdil V, Viethen T, Neumann C, Mundl H, Patel MR; PACIFIC-AF Investigators.
Piccini JP, et al.
Lancet. 2022 Apr 9;399(10333):1383-1390. doi: 10.1016/S0140-6736(22)00456-1. Epub 2022 Apr 3.
Lancet. 2022.
PMID: 35385695
Clinical Trial.
Item in Clipboard
Cite
Cite